Hepatitis b and hepatitis c reactivation in the biologic era

Journal of Clinical and Translational Hepatology

Volumn 2, Issue 4, 2014, Pages 240-246

  Bojito Marrero, Lizza ^a   Pyrsopoulos, Nikolaos ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Biologics; Hepatitis B reactivation; Hepatitis C reactivation; Immunosuppressive therapy; Prophylactic antiviral treatment

Indexed keywords

EID: 84979644684     PISSN: 22250719     EISSN: 23108819     Source Type: Journal    
DOI: 10.14218/JCTH.2014.00033     Document Type: Review

References (59)

1. Weinbaum CM, Mast EE, Ward JW. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology 2009;49:S35–S44. doi: 10.1002/hep.22882.
2. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011;31:1090–1101. doi: 10.1111/j.1478-3231.2011.02494.x.
3. Yeo W, Zee B, Zhong S, Chan PKS, Wong W-L, Ho WM, et al. Comprehensive analysis of risk factors associating with hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004;90: 1306–1311 doi: 10.1038/sj.bjc.6601699.
4. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182–188.
5. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987–1991. Cancer 1996;78:2210–2215. doi: 10.1002/(SICI)1097-0142(19961115)78:10,2210::AID-CNCR24. 3.0.CO;2-0.
6. Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997;8(Suppl 1):107–109.
7. Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev ClinOncol 2012;9:156–166. doi: 10.1038/nrclinonc.2012.1.
8. Zuckerman E, Zuckerman T, Douer D, Qian D, Levine AM. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 1998;83:1224–1230. doi: 10.1002/(SICI)1097-0142(19980915)83:6,1224::AID-CNCR23.3.0.CO;2-6.
9. Luppi M, Longo G, Ferrari MG, Ferrara L, Marasca R, Barozzi P, et al. Additional neoplasms and HCV infection in low-grade lymphoma of MALT type. Br J Haematol 1996;94:373–375.
10. Vento S, Cainelli F, Mirandola F, Cosco L, Di Perri G, Solbiati M, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996;347:92–93. doi: 10.1016/S0140-6736(96)90212-3.
11. Kawatani T, Suou T, Tajima F, Ishiga K, Omura H, Endo A, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 2001;67:45–50. doi: 10.1034/j.16000609.2001.067001045.x.
12. Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002;3:333–340. doi: 10.1016/S1470-2045(02)00773-8.
13. Mahale P, Kontoyiannis DP, Chemaly RF, Jiang Y, Hwang JP, Davila M, et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol 2012;57:1177–1185. doi: 10.1016/j.jhep. 2012.07.031.
14. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209–220. doi: 10.1002/hep.21051.
15. Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol 2010; 25:864–871. doi: 10.1111/j.1440-1746.2010.06243.x.
16. Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol 2010;29:1021–1029. doi: 10.1007/s10067-010-1523-2.
17. Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010;89: 255–262. doi: 10.1007/s00277-009-0806-7.
18. Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006;45:721–724. doi: 10.2169/internalmedicine.45.1590.
19. Iannitto E, Minardi V, Calvaruso G, Mulè A, Ammatuna E, Di Trapani R, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 2005;74:254–258. doi: 10.1111/j.1600-0609.2004.00375.x.
20. Moses SE, Lim ZY, Sudhanva M, Devereux S, Ho AY, Pagliuca A, et al. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. J Med Virol 2006;78:1560–1563. doi: 10.1002/jmv. 20705.
21. Mitka M. FDA: Increased HBV Reactivation Risk withOfatumumab or Rituximab. JAMA 2013;310:1664. doi: 10.1001/jama.2013.281115.
22. Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y. Risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients receiving rituximab-che-motherapy: A meta-analysis. J Clin Virol 2013;57:209–214. doi: 10.1016/j.jcv.2013.03.010.
23. Lee YH, Bae SC, Song GG. Hepatitis B virus reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2013;31:118–121.
24. Sheen IS, Liaw YF, Lin SM, Chu CM. Severe clinical rebound upon withdrawal of corticosteroid before interferon therapy: incidence and risk factors. J Gastroenterol Hepatol 1996;11:143–147.
25. Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regi-mens: a Japanese multicenter analysis. Blood 2010;116:5119–5125. doi: 10.1182/blood-2010-06-289231.
26. Aksoy S, Abali H, Kilickap S, Erman M, Kars A. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin’s lymphoma patient. Clin Lab Haematol 2006;28:211–214. doi: 10.1111/j.1365-2257.2006.00779.x.
27. Tsutsumi Y, Ichiki K, Shiratori S, Kawamura T, Tanaka J, Asaka M, et al. Changes in hepatitis C virus antibody titer and viral RNA load in non-Hodgkin’s lymphoma patients after rituximab chemotherapy. Int J Lab Hematol 2009;31:468–470. doi: 10.1111/j.1751-553X.2008.01034.x.
28. Nooka A, Shenoy P J, Sinha R, Lonial S, Flowers CR. Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature. Clin Lymphoma Myeloma Leuk 2011;11: 379–384. doi: 10.1016/j.clml.2011.04.005.
29. Ciesek S, Steinmann E, Iken M, Ott M, Helfritz FA, Wappler I, et al. Gl ucocort i cost eroi ds Increase Cel l Entry by Hepat i t i s C Vi rus. Gastroenterology 2010;138:1875–1884. doi: 10.1053/j.gastro.2010. 02.004.
30. Liu CJ, Kao JH. Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir Ther 2008;13:613–624.
31. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661–662. doi: 10.1002/hep.23190.
32. Coursaget P, Yvonnet B, Chotard J, Vincelot P, Sarr M, Diouf C, et al. Age-and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). J Med Virol 1987;22:1–5. doi: 10.1002/jmv.189 0220102.
33. McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Diseases 1985;151:599–603. doi: 10.1093/infdis/151.4.599.
34. Tassopoulos NC, Papaevangelou GJ, Sjogren MH, Roumeliotou-Karayannis A, Gerin JL, Purcell RH. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 1987;92:1844–1850.
35. http://emedicine.medscape.com/article/177632, accessed December, 2013.
36. Tran TT. Immune tolerant hepatitis B: a clinical dilemma. Gastroenterol Hepatol 2011;7:511–516.
37. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582–592. doi: 10.1016/S0140-6736(09)60207-5.
38. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009;49:S156–S165. doi: 10.1002/hep.22945.
39. Mastroianni CM, Lichtner M, Citton R, Del Borg C, Rago A, Martini H, et al. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol 2011;17:3881–3887. doi: 10.3748/wjg.v17.i34.3881.
40. Watanabe T, Tanaka Y. Reactivation of hepatitis viruses following immuno-modulating systemic chemotherapy. Hepatol Res 2013;43:113–121. doi: 10.1111/hepr.12014.
41. Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013;31:2765–2772. doi: 10.1200/JCO.2012.48.5938.
42. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519–528. doi: 10.7326/0003-4819-148-7-200804010-00008.
43. Li HR, Huang JJ, Guo HQ, Zhang X, Xie Y, Zhu HL, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat 2011;18:877–883. doi: 10.1111/j.1365-2893.2010.01386.x.
44. Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011;141:1212–1219. doi: 10.1053/j.gastro.2011.06.083.
45. European Association For The Study Of The Liver, Papatheodoridis G, Buti M, Cornberg M, Janssen HL, Mutimer D, et al. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167– 185. doi: 10.1016/j.jhep.2012.02.010.
46. Sperl J, Frankova S, Kieslichova E, Oliverius M, Janousek L, Honsova E, et al. Urgent liver transplantation for chemotherapy-induced HBV reactivation: A suitable option in patients recently treated for malignant lymphoma. Transplant Proc 2013;45:2834–2837. doi: 10.1016/j.transproceed.2013. 03.047.
47. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335–1374. doi: 10.1002/hep.22759.
48. Morisco F, Castiglione F, Rispo A, Stroffolini T, Sansone S, Vitale R, et al. Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. J Viral Hepat 2013;20:200– 208. doi: 10.1111/j.1365-2893.2012.01643.x.
49. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Viral Hepat 2014; 60:392–420. doi: 10.1016/j.jhep.2013.11.003.
50. Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001;234:384–393. doi: 10.1097/00000658-200109000-00012.
51. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002;35:680–687. doi: 10.1053/jhep.2002.31773.
52. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004;77:226–231. doi: 10.1097/01.TP.000010 1738.27552.9D
53. Haji SA, Starling RC, Avery RK, Mawhorter S, Tuzcu EM, Schoenhagen P, et al. Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant 2004;23:277–283. doi: 10.1016/S1053-2498(03)00148-7.
54. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315–22. doi: 10.1016/j.jhep.2004.11.025.
55. http://www.hcvguidelines.org/sites/default/files/full_report.pdf, accessed February, 2014.
56. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878–1887. doi: 10.1056/NEJMoa1214853.
57. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir + Ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Hepatology 2013;58(Suppl):733A.
58. Jacobson IM, Ghalib RH, Rodriguez-Torres M, Younossi ZM, Corregidor A, Sulkowski MS, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: The COSMOS study. Hepatology 2013;58(Suppl):1379A.
59. Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531–561. doi: 10.1007/s12072-012-9365-4.